BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.

科罗拉多州博尔德，2024年4月9日（环球通讯社）--Enliven Therapeutics，Inc.（Enliven或该公司）（纳斯达克：ELVN），一家专注于发现和开发下一代小分子激酶抑制剂的临床阶段精准肿瘤学公司，今天宣布任命医学博士Lori Kunkel为董事会成员。

Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. “Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board,” said Sam Kintz, MBA, Enliven’s Co-founder and Chief Executive Officer.

Kunkel博士为董事会带来了超过25年的肿瘤学和免疫学药物开发和商业化经验。“Lori自Enliven成立以来一直担任科学顾问，我们很高兴现在欢迎她加入我们的董事会，”Enliven联合创始人兼首席执行官、MBA萨姆·金茨（SamKintz）表示。

“She brings a wealth of experience as a clinician, academic and industry executive, and we look forward to her continued contributions and insights as we advance our two parallel lead product candidates, ELVN-001 and ELVN-002, through the next set of clinical milestones.” Dr. Kunkel is an accomplished industry executive and board member with a track record of success in corporate strategy, clinical development and commercialization, and business development.

“她作为临床医生、学术界和行业高管拥有丰富的经验，我们期待着她在推动我们的两个平行领先产品候选人ELVN-001和ELVN-002通过下一组临床里程碑时继续做出贡献和见解。”Kunkel博士是一位有成就的行业高管和董事会成员，在公司战略、临床开发和商业化以及业务发展方面取得了成功。

She currently serves on the Board of Directors of Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36 Therapeutics, Inc. She is also a scientific advisor to several clinical-stage oncology and immunotherapy companies. Previously, Dr. Kunkel was the acting Chief Medical Officer (CMO) and board member of Loxo Oncology, Inc.

她目前担任Nurix Therapeutics，Inc.，ORIC Pharmaceuticals，Inc.和K36 Therapeutics，Inc.的董事会成员。她还是多家临床阶段肿瘤和免疫治疗公司的科学顾问。此前，Kunkel博士是Loxo Oncology，Inc.的代理首席医疗官（CMO）和董事会成员。

(acquired by Eli Lilly and Company). She also served as the CMO at Pharmacyclics LLC (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals). Prior to joining industry, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hemato.

（由礼来公司收购）。她还曾担任Pharmacyclics LLC（被AbbVie收购）和Proteolix，Inc.（被Onyx Pharmaceuticals收购）的首席营销官。在加入业界之前，Kunkel博士在学术医学领域工作了十年，并在血液科的骨髓移植部门担任教员。